Spots Global Cancer Trial Database for hcd122
Every month we try and update this database with for hcd122 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy | NCT00108108 | Chronic Lymphoc... | HCD122 | 18 Years - | Novartis | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | NCT00231166 | Multiple Myelom... | HCD122 | 18 Years - 100 Years | Novartis | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy | NCT00108108 | Chronic Lymphoc... | HCD122 | 18 Years - | Novartis | |
| Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma | NCT01275209 | Follicular Lymp... | HCD122 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
